BioCT Launches New England Edge Purchasing Program
Introducing New England Edge, our new, exclusive purchasing program powered by MassBio. As a dedicated supporter of Connecticut’s bioscience industry, BioCT is constantly evaluating the...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Introducing New England Edge, our new, exclusive purchasing program powered by MassBio. As a dedicated supporter of Connecticut’s bioscience industry, BioCT is constantly evaluating the...
Alexion Pharmaceuticals reports that the European Commission has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica...
BioXcel Therapeutics reports that the FDA has granted Orphan Drug Designation for BXCL701, an investigational orally-available systemic innate immunity activator with dual mechanisms of action,...
SpringWorks Therapeutics reports that the FDA has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients...
Tuesday’s Yale Entrepreneurship & Innovation Expo brought together Yale’s many entrepreneurial organizations and clubs for a three-hour meet-and-greet with one another and members of the...
Connecticut Governor Ned Lamont, U.S. Sen. Richard Blumenthal, and other luminaries were on hand recently when Tangen Biosciences unveiled its new 16,300-square-foot facility at 20 Commerce Drive...
Arvinas has announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-471, an oral estrogen receptor (ER)-targeting...
Certain types of bacteria are capable of causing colorectal cancers, indicating that a sub-set of these cancers could be the result of infectious disease. There...
BioXcel Therapeutics reports that the U.S. DoD’s CDMRP has awarded a planning grant1 as a part of its Alcohol and Substance Abuse Disorders Research Program...
SpringWorks Therapeutics has filed to raise $115 million in an IPO. The money will take SpringWorks through to regulatory filings for two former Pfizer drugs against...